A Year in Review: Experts Illuminate the Potential of ADCs Targeting HER2, HER3, and TROP-2 in NSCLC

Learn how experts are integrating the latest data on ADCs into clinical care of NSCLC with downloadable slides and an archived webcast of a live webinar, along with a focused commentary.

Share

Program Content

Activities

ADCs for NSCLC
My Take on Recent Developments in Antibody‒Drug Conjugates for NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2023

View Activity

Activities

HER2 ADCs in NSCLC
A Year in Review: ADCs Targeting HER2 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

View Activity
TROP-2 ADCs in NSCLC
A Year in Review: ADCs Targeting TROP-2 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

View Activity
HER3 ADCs in NSCLC
A Year in Review: ADCs Targeting HER3 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

View Activity

Activities

Targeted ADCs in NSCLC
Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 05, 2024

Expires: February 04, 2025

View Activity

Faculty

cover img faculity

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

cover img faculity

Helena Yu, MD

Associate Attending
Research Director of Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.